Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2022-10-17 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
上海泓博智源医药股份有限公司首次公开发行股票并在创业板上市发行公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd., including information about the stock issuance, pricing, subscription process, investor instructions, regulatory approvals, and risk disclosures. It references regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed procedural and pricing information for the IPO. The document is not a financial report like an annual or quarterly report, nor is it a transcript, audit report, or management change announcement. It is a comprehensive issuance announcement related to capital raising and stock issuance. Therefore, the document fits best into the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement of a report but a substantive disclosure about the financing event.
2022-10-17 Chinese
上海泓博智源医药股份有限公司首次公开发行股票并在创业板上市网上路演公告
Investor Presentation Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd., including details about the stock issuance, pricing, allocation, and an online roadshow for investors. It mentions the approval by the China Securities Regulatory Commission and the Shenzhen Stock Exchange, and provides information about the underwriting and strategic placement. The document is relatively short (2400 characters) and serves as a notice for an upcoming investor presentation event rather than the presentation itself or a detailed financial report. It is not a full financial report, earnings release, or regulatory filing of financial results. The content fits best as an Investor Presentation (IP) announcement or related material, but since it is specifically about the online roadshow for the IPO, it aligns with Investor Presentation (IP) category, which covers detailed presentations for investors focusing on financials, strategy, and market position, including IPO roadshows.
2022-10-16 Chinese
股东大会有关本次发行并上市的决议
Regulatory Filings
2022-09-29 Chinese
发行人监事对招股书的确认意见
Regulatory Filings Classification · 95% confidence The document is a confirmation opinion from the company's supervisors regarding the prospectus for the company's initial public offering (IPO) on the Growth Enterprise Market. It is a signed statement confirming the accuracy and completeness of the prospectus, not the prospectus itself or a financial report. The document is very short (430 characters) and serves as a certification or attestation related to a regulatory filing. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2022-09-29 Chinese
发行人及其实际控制人、控股股东、持股5%以上股东以及发行人董事、监事、高级管理人员等责任主体的重要承诺以及未履行承诺的约束措施
Regulatory Filings
2022-09-29 Chinese
发行人关于公司设立以来股本演变情况的说明及其董事、监事、高级管理人员的确认意见
Major Shareholding Notification Classification · 95% confidence The document is a detailed explanation and confirmation regarding the evolution of the company's share capital since its establishment, including historical capital contributions, share transfers, and changes in shareholder structure. It includes confirmations from the company's directors, supervisors, and senior management about the legality and compliance of these changes. There is no indication that this is a financial report like an annual or interim report, nor is it a simple announcement or certification. The content focuses on share capital evolution and related confirmations by management, which aligns with disclosures about shareholding and capital changes. However, it is not a simple share issue announcement but a comprehensive explanation and confirmation document. Given the detailed nature and the focus on share capital evolution and shareholder confirmations, the most appropriate classification is Major Shareholding Notification (MRQ), as it deals with significant share ownership changes and confirmations thereof.
2022-09-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.